Onconetix Inc
For the period ended Jun 30, 2024. Filed Aug 29, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 29, 2024
ONCO$3.47-3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(25,425,276) | $(9,711,914) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Impairment of deposit on asset purchase agreement | — | 3,500,000 |
| Impairment of goodwill | 15,453,000 | — |
| Impairment of ENTADFI assets | 3,530,716 | — |
| Amortization of debt discounts | 291,959 | 213,996 |
| Amortization of debt discount – related party | 293,820 | — |
| Loss on related party receivable | — | 165,355 |
| Depreciation and amortization | 408,001 | 3,269 |
| Change in fair value of subscription agreement liability – related party | 21,600 | — |
| Net periodic pension benefit | (24,868) | — |
| Stock-based compensation | 51,875 | 458,359 |
| Interest accrued on note payable | 95,751 | — |
| Interest accrued on note payable – related party | 87,123 | — |
| Loss on impairment of inventory of ENTADFI | 356,637 | — |
| Change in fair value of contingent warrant liability | — | 59 |
| Deferred tax benefit | (70,799) | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (31,501) | — |
| Inventories | (159,095) | (51,900) |
| Prepaid expenses and other current assets | (220,928) | (227,201) |
| Prepaid expenses, long-term | (7,749) | (16,882) |
| Accounts payable | (2,188,629) | 427,409 |
| Accrued expenses | (893,228) | (989,319) |
| Net cash used in operating activities | (8,431,591) | (6,228,769) |
| Cash flows from investing activities | ||
| Acquisition of assets, including transaction costs of $79,771 | — | (6,079,771) |
| Deposit made in connection with asset purchase agreement | — | (3,500,000) |
| Net advances to related parties | — | (454,557) |
| Purchases of property and equipment | (22,284) | (3,300) |
| Net cash used in investing activities | (22,284) | (10,037,628) |
| Cash flows from financing activities | ||
| Proceeds from issuance of note payable – related party | 5,000,000 | — |
| Proceeds from issuance of note payable | 678,550 | — |
| Payment of financing costs | (400,000) | — |
| Principal payments of notes payable | (417,046) | — |
| Proceeds from exercise of stock options | 163 | 459 |
| Payment of deferred offering costs | — | (205,093) |
| Purchase of treasury shares | — | (58,981) |
| Net cash provided by (used in) financing activities | 4,861,667 | (263,615) |
| Effect of exchange rate changes on cash | (31,586) | — |
| Net decrease in cash | (3,623,794) | (16,530,012) |
| Cash, beginning of period | 4,554,335 | 25,752,659 |
| Cash, end of period | $930,541 | $9,222,647 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $4,405 | $— |
| Noncash investing and financing activities: | ||
| Inventory and intangible assets acquired through issuance of notes payable | $— | $12,947,000 |
| Deferred offering costs included in accounts payable and accrued expenses | $— | $150,000 |
| Deferred offering costs previously included in prepaid expenses | $— | $(11,020) |
| Exercise of pre-funded warrants | $— | $7 |
| Issuance of restricted stock | $— | $5 |
| Operating right-of-use asset obtained in exchange of lease liability | $87,864 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.